A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
616 patients around the world
Available in Brazil, Mexico
Samsung Bioepis Co., Ltd.
616Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Male or female ≥ 18 years of age.
Have been diagnosed with stage IV non-squamous NSCLC.
Have not received any prior systemic anti-cancer therapy for metastatic NSCLC.
Agree to use adequate methods of contraception.
Unable or unwilling to take folic acid and vitamin B12 supplementation.
Severe hypersensitivity to treatment with another monoclonal antibody, any ingredient contained in SB27 or Keytruda, or any component of platinum-containing compounds or pemetrexed.
